Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Clinical trial NCT04776876 · WITHDRAWN
Trial details
- NCT number
- NCT04776876
- Sponsor
- M.D. Anderson Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2021-09-02
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.